Promoting longevity in aged liver through NLRP3 inflammasome inhibition using tauroursodeoxycholic acid (TUDCA) and SCD probiotics

dc.contributor.authorBaba, Burcu
dc.contributor.authorCeylani, Taha
dc.contributor.authorGurbanov, Rafig
dc.contributor.authorAcikgoz, Eda
dc.contributor.authorAllahverdi, Hueseyin
dc.contributor.authorKeskin, Seda
dc.contributor.authorSamgane, Gizem
dc.date.accessioned2024-12-14T22:07:17Z
dc.date.available2024-12-14T22:07:17Z
dc.date.issued2024
dc.departmentMuş Alparslan Üniversitesien_US
dc.description.abstractThis investigation explores the combined influence of SCD Probiotics and tauroursodeoxycholic acid (TUDCA) on liver health in elderly male Sprague-Dawley rats. Through the administration of intravenous TUDCA (300 mg/ kg) and oral SCD Probiotics (3 mL at 1 x 10<^>8 CFU) daily for one week, this study evaluates the biomolecular composition, histopathological alterations, and inflammasome activity in the liver. Analytical methods encompassed ATR-FTIR spectroscopy integrated with machine learning for the assessment of biomolecular structures, RT-qPCR for quantifying inflammasome markers (NLRP3, ASC, Caspase-1, IL18, IL1 beta), and histological examinations to assess liver pathology. The findings reveal that TUDCA prominently enhanced lipid metabolism by reducing cholesterol esters, while SCD Probiotics modulated both lipid and protein profiles, notably affecting fatty acid chain lengths and protein configurations. Histological analysis showed significant reductions in cellular degeneration, lymphatic infiltration, and hepatic fibrosis. Furthermore, the study noted a decrease in the immunoreactivity for NLRP3 and ASC, suggesting suppressed inflammasome activity. While SCD Probiotics reduced the expression of certain inflammasome-related genes, they also paradoxically increased AST and LDH levels. Conversely, an exclusive elevation in albumin levels was observed in the group treated with SCD Probiotics, implying a protective role against liver damage. These results underscore the therapeutic potential of TUDCA and SCD Probiotics for managing age -associated liver disorders, illustrating their individual and synergistic effects on liver health and pathology. This study provides insights into the complex interactions of these agents, advocating for customized therapeutic approaches to combat liver fibrosis, enhance liver functionality, and decrease inflammation in aging populations.en_US
dc.identifier.doi10.1016/j.archger.2024.105517
dc.identifier.issn0167-4943
dc.identifier.issn1872-6976
dc.identifier.orcid0000-0003-0994-3577
dc.identifier.pmid38851091
dc.identifier.scopus2-s2.0-85195198634
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.archger.2024.105517
dc.identifier.urihttps://hdl.handle.net/20.500.12639/6522
dc.identifier.volume125en_US
dc.identifier.wosWOS:001263763100001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofArchives of Gerontology and Geriatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_20241214
dc.subjectTUDCAen_US
dc.subjectSCD Probioticsen_US
dc.subjectNLRP3 inflammasomeen_US
dc.subjectInflammationen_US
dc.subjectFibrosisen_US
dc.subjectLiveren_US
dc.subjectATR-FTIRen_US
dc.titlePromoting longevity in aged liver through NLRP3 inflammasome inhibition using tauroursodeoxycholic acid (TUDCA) and SCD probioticsen_US
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
6522.pdf
Boyut:
7.84 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text